Abstracts Archive - Page 574 of 2425 - ACR Meeting Abstracts

Abstract Number: 0329 • ACR Convergence 2021
Racial and Ethnic Disparities in Risk of End-Organ Disease Following SLE Diagnosis in a Multi-Ethnic Cohort
ALFREDO AGUIRRE¹, Andrea Seet¹, Laura Trupin², Patricia Katz¹, Kamil Barbour³, Cristina Lanata⁴, Maria Dall'Era⁵ and Jinoos Yazdany¹, ¹University of California San Francisco, San Francisco, CA, ²UC San Francisco, San Francisco, CA, ³Centers for Disease Control, Atlanta, GA, ⁴University of California San Francisco, Moss Beach, CA, ⁵University of California San Francisco, Corte Madera, CA
Background/Purpose: Racial and ethnic minorities experience a disproportionate burden of systemic lupus erythematosus (SLE) as well as earlier development of lupus manifestations as compared to…
Abstract Number: 0328 • ACR Convergence 2021
Natural Language Processing to Identify Lupus Nephritis Phenotype in Electronic Health Records
Yu Deng¹, Jennifer Pacheco¹, Anh Chung¹, Chengsheng Mao¹, Joshua Smith², juan zhao¹, Wei-Qi Wei², April Barnado³, Chunhua Weng⁴, Cong Liu⁴, Adam Gordon¹, Jingzhi Yu¹, Yacob Tedla¹, Abel Kho¹, Rosalind Ramsey-Goldman¹, Theresa Walunas¹ and Yuan Luo¹, ¹Northwestern University, Chicago, IL, ²Vanderbilt Universty Medical Center, Nashville, TN, ³Vanderbilt University Medical Center, Nashville, TN, ⁴Columbia University, New York, NY
Background/Purpose: Lupus nephritis (LN) is a major disease manifestation of Systemic lupus erythematosus (SLE) leading to organ damage and increased mortality. Accurately identifying lupus nephritis…
Abstract Number: 0327 • ACR Convergence 2021
Lipoprotein(a) in Systemic Lupus Erythematosus Is Associated with History of Proteinuria and Renal Insufficiency
Caoilfhionn Connolly¹, Jessica Li², Daniel Goldman³, Andrea Fava², Laurence Magder⁴ and Michelle Petri³, ¹Johns Hopkins, Baltimore, MD, ²Johns Hopkins University, Baltimore, MD, ³Johns Hopkins University School of Medicine, Baltimore, MD, ⁴University of Maryland, Baltimore, Baltimore, MD
Background/Purpose: Lipoprotein(a) [Lp(a)] is a well-recognized, independent risk factor for atherosclerotic cardiovascular disease. Cardiovascular disease is one of the leading causes of death in patients…
Abstract Number: 0322 • ACR Convergence 2021
Histopathological Changes in Parotid and Labial Salivary Gland Tissue in Primary Sjögren’s Syndrome Patients After Abatacept Treatment
Uzma Nakshbandi¹, Liseth de Wolff², Frans Kroese¹, Silvia Liefers³, Neelanjana Ray⁴, Gwenny Verstappen¹, Fred Spijkervet³, Marleen Nys⁵, Arjan Vissink⁶, Robert Wong⁷, Bert van der vegt³ and Hendrika Bootsma¹, ¹University Medical Center Groningen, Groningen, Netherlands, ²University Medical Centre Groningen, Groningen, Netherlands, ³University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ⁴Bristol-Myers Squibb Company, Lawrenceville, GA, ⁵Bristol Myers Squibb, Braine-l'Alleud, Belgium, ⁶University of Groningen, University Medical Center Groningen, Leek, Netherlands, ⁷Bristol Myers Squibb, Basking Ridge, NJ
Background/Purpose: In a previous open-label phase II study, we showed that abatacept treatment might inhibit local formation of autoreactive memory B cells in parotid glands…
Abstract Number: 0333 • ACR Convergence 2021
Validation of the 2019 European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) Classification Criteria for Systemic Lupus Erythematosus (SLE) in Hong Kong Chinese
Chi Chiu Mok¹, Yuen Kwan Chung², Carolyn Lee³, Ling Yin Ho⁴ and Chi Hung To², ¹Tuen Mun Hospital, Hong Kong, China, ²Pok Oi Hospital, Hong Kong, Hong Kong, ³Hospital Authority, Hong Kong, Hong Kong, ⁴Tuen Mun Hospital, Hong Kong, Hong Kong
Background/Purpose: To validate the 2019 EULAR/ACR classification criteria for SLE in Hong Kong Chinese patients and compare its performance with the 2012 Systemic Lupus International…
Abstract Number: 0332 • ACR Convergence 2021
Prevalence of Systemic Lupus Erythematosus in the United States: Updated Population Representative Estimates from the Medical Expenditure Panel Survey (MEPS) 2016-2018
Michael Pollack¹, Sandra Sze-jung Wu¹, Eilleen Farrelly², Shannon Grabich³ and Robert Ortmann⁴, ¹AstraZeneca, Wilmington, DE, ²Xcenda, Carrollton, TX, ³Xcenda, Durham, NC, ⁴AstraZeneca, Greenwood, IN
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic, multi-organ, autoimmune disease whose prevalence in the US has not been recently updated in real-world studies. Prevalence…
Abstract Number: 0330 • ACR Convergence 2021
Serologic Phenotypes Distinguish SLE Patients with Myositis And/or Interstitial Lung Disease (ILD)
Thaisa Cotton¹, Marvin Fritzler², May Choi³, Boyang Zheng⁴, Omid Zahedi Niaki⁵, Louis-Pierre Grenier⁵, Evelyne Vinet⁶, Christian Pineau¹, Luck Lukusa⁷, Fares Kalache⁵ and Sasha Bernatsky¹, ¹McGill University, Montréal, QC, Canada, ²University of Calgary, Calgary, AB, Canada, ³Brigham and Women's Hospital | University of Calgary, Calgary, AB, Canada, ⁴University of British Columbia, Vancouver, BC, Canada, ⁵McGill University Health Centre, Montréal, QC, Canada, ⁶McGill University Health Centre, Mont Royal, QC, Canada, ⁷Research Institute of the McGill University Health Centre, Montréal, QC, Canada
Background/Purpose: To determine if a serologic phenotype can be identified in SLE patients with myositis and/or ILD.Methods: Adult SLE patients (without myositis or ILD at…
Abstract Number: 0334 • ACR Convergence 2021
Association Between Systemic Lupus Erythematosus and Myasthenia Gravis: A Population-Based National Study
Sali Merjanah¹, Ann Igoe², David Kaelber³ and Robert Hal Scofield⁴, ¹Boston University, Boston, MA, ²OhioHealth Hospital, Mansfield, OH, ³The MetroHealth System Campus of Case Western Reserve University, Cleveland, OH, ⁴Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Systemic lupus erythematosus (SLE) and myasthenia gravis (MG) are two autoimmune disorders that have a young female preponderance, relapsing-remitting course, and positive antinuclear antibodies.…
Abstract Number: 0336 • ACR Convergence 2021
The Incremental Clinical Utility of a Multianalyte Assay Panel with Cell-Bound Complement Activation Products versus a Traditional ANA Testing Strategy for the Diagnosis and Treatment of SLE
Tyler O'Malley¹, Fenglong Xie², yujie Su², cassie Clinton², Debra J. Zack¹, Jeffrey Curtis³ and John Wegener¹, ¹Exagen Inc., Vista, CA, ²University of Alabama at Birmingham, Birmingham, AL, ³Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: The comparative clinical utility of various diagnostic tests to aid the differential diagnosis of SLE is unclear. We compare the outcomes of testing with…
Abstract Number: 0335 • ACR Convergence 2021
Performances of Different Classification Criteria for Systemic Lupus Erythematosus in a Single Center Cohort from Turkey
Ege Sinan Torun¹, Erdem Bektaş¹, Fatih Kemik², Murat Bektaş³, Cigdem Cetin⁴, Yasemin Yalcinkaya⁴, Bahar Esen⁴, Ahmet Gül⁵ and Murat Inanc⁶, ¹Istanbul University Istanbul Faculty of Medicine, İstanbul, Turkey, ²Istanbul Faculty of Medicine, Istanbul University, Department of Internal Medicine, İstanbul, Turkey, ³Istanbul Faculty of Medicine, Istanbul, Turkey, ⁴Division of Rheumatology, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey, ⁵Division of Rheumatology, Istanbul University Istanbul School of Medicine, Istanbul, Turkey, ⁶Istanbul University Faculty of Medicine, Istanbul, Turkey
Background/Purpose: Recently developed EULAR/ACR classification criteria for systemic lupus erythematosus (SLE) has important differences compared to the 2012 Systemic Lupus International Collaborating Clinics (SLICC) SLE…
Abstract Number: 0331 • ACR Convergence 2021
Urinary MicroRNAs as Systemic Lupus Erythematosus Biomarkers and Its Potential for Accurate Assessment of Disease Severity
Hiroki Yamaguchi¹, Yoriko Ando¹, Mika Mizunuma¹, Masamichi Inami², Kenichi Suzumura² and Yuki Ichikawa¹, ¹Craif Inc., Nagoya, Japan, ²Analysis & Pharmacokinetics Research Labs., Astellas Pharma Inc., Tsukuba, Japan
Background/Purpose: Systemic lupus erythematosus (SLE) is a systemic autoimmune disease characterized by autoantibody production, immune complex deposition, and heterogeneous clinical manifestations affecting many organs, including…
Abstract Number: 0325 • ACR Convergence 2021
A Multianalyte Assay Panel with Cell-bound Complement Activation Products Demonstrates Clinical Utility for the Diagnosis and Treatment of Systemic Lupus Erythematosus
Roberta Alexander¹, Scott Rey¹, John Conklin¹, Vinicius Domingues², Mansoor Ahmed³, Jazibeh Qureshi⁴ and Arthur Weinstein⁵, ¹Exagen Inc., Vista, CA, ²Florida State university, Daytona beach, FL, ³Arthritis Osteo Ctr of KY, Richmond, KY, ⁴Rheumatology Express, Catonsville, MD, ⁵Loma Linda University (Voluntary Position), Claremont, CA
Background/Purpose: The multianalyte assay panel (MAP) consists of cell-bound complement activation products (CB-CAPs) with lupus and non-lupus autoantibodies combined in an algorithm (Dervieux et al.,…
Abstract Number: 0306 • ACR Convergence 2021
Allergic Disorders in Primary Sjögren’s Syndrome Compared with Rheumatoid Arthritis
Misako Higashida-Konishi¹, Keisuke Izumi², Tatsuya Shimada³, Satoshi Hama⁴, Mitsuhiro Akiyama⁵, Hisaji Oshima⁴ and Yutaka Okano⁶, ¹Department of Connective Tissue Diseases, National Hospital Organization Tokyo Medical Center, Meguroku, Japan, ²Department of Connective Tissue Diseases, National Hospital Organization Tokyo Medical Center/Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ³Department of Connective Tissue Diseases, National Hospital Organization Tokyo Medical Center/ Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, ⁴Department of Connective Tissue Diseases, National Hospital Organization Tokyo Medical Center, tokyo, Japan, ⁵Department of Connective Tissue Diseases, National Hospital Organization Tokyo Medical Center/ Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Palo Alto, CA, ⁶Department of Connective Tissue Diseases, National Hospital Organization Tokyo Medical Center, Kawasaki, Japan
Background/Purpose: Allergic disorders are occasionally seen in patients with primary Sjögren's syndrome (pSS) [1]. Risk factors are unclear for allergic disorders.We aimed to compare the…
Abstract Number: 0277 • ACR Convergence 2021
Best Cardiovascular Risk Algorithm to Predict Abnormalities in Left Ventricular Geometry in Rheumatoid Arthritis Patients
Alejandra Rodriguez-Romero, Jose Azpiri-Lopez, Dionicio Galarza-Delgado, Iris Colunga-Pedraza, Jose A. Davila-Jimenez, Natalia Guajardo-Jauregui, Alejandro Meza-Garza, Julieta Loya-Acosta, Jesus Cardenas-de La Garza, Salvador Lugo-Perez, Alan De Leon-Yañez and Catalina Andrade-Vazquez, Hospital Universitario "Dr Jose E. Gonzalez", Monterrey, Mexico
Background/Purpose: A relationship between rheumatoid arthritis (RA) and the presence of abnormalities in left ventricular (LV) geometry such as eccentric remodeling has recently been determined,…
Abstract Number: 0214 • ACR Convergence 2021
Baseline Cam or Pincer Morphology Is Associated with Loss of Quantitative Joint Space Width at the Hip: The Johnston County Osteoarthritis Project
Amanda Nelson¹, Carolina Alvarez¹, Yvonne Golightly¹, Jamie Stiller², Jordan Renner¹, Nigel Arden³, Charles Ratzlaff⁴ and Jeffrey Duryea⁵, ¹University of North Carolina at Chapel Hill, Chapel Hill, NC, ²Alamance Regional Medical Center, Durham, NC, ³University of Oxford, Oxford, United Kingdom, ⁴University of British Columbia, Vancouver, BC, Canada, ⁵Brigham and Women's Hospital, Boston, MA
Background/Purpose: To determine the association between radiographic cam and pincer morphology and loss of hip quantitative joint space width (qJSW) in a community-based cohort.Methods: Data…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].